The present invention relates generally to an integrated medication packaging and labeling system and more specifically to a prescription medication packaging and labeling system, which is designed to clearly provide information about the medication in order to avoid misuse of the medication.
The present invention also relates independently to a label for prescription medication, a method for generating a label for prescription medication, a container for prescription medication and an information card for prescription medication.
Unfortunately, there are numerous instances in which prescription medication is misused with harmful and often fatal results. Misuse may involve a variety of different factors, such as taking the correct medication in an improper manner, at an incorrect time schedule and/or at an incorrect time with respect to meals, as well as taking the incorrect medication resulting from similarities between the shape, size, name and/or color of different medication and the bottles or containers in which different medications are dispensed.
Medication misuse often involves people, e.g., elderly people, who have difficulty reading and/or understanding the directions for using a particular medication. For example, it is known that Cardizem CD™, a prescription medication for blood pressure control, must be swallowed whole in order to be effective. This fact is indicated on the label that accompanies dispensation of the medication. However, elderly people may experience problems swallowing a large capsule and therefore might resort to breaking the capsule into smaller parts or chewing the capsule. This negates the pharmacological effects of the medication so that even though the patient is taking the medication, the desired control of the blood pressure is not being obtained in view of the misuse of the medication.
In the. U.S., almost as much money is spent addressing the complications caused by home medication errors as is spent purchasing all the medications dispensed. Three years ago, almost 76 billion a year was spent purchasing medications in the U.S. while another 76 billion was spent treating medication errors including, but not limited to, errors caused by complications experienced by individuals as a result of misunderstandings in taking their medications. The cost of home medication increases (180 billion+) when the costs to an employer for absenteeism, on-the-job injuries, etc. are included. Home medication errors are a national public health issue that is harming patients and the health care system, as well as the productivity of the U.S.
When a person is non-adherent, i.e., does not follow the proper instructions for taking medication, the cost of the treatment increases for both the consumer and the health care insurance provider. The wise use of prescription drugs can save lives. Prescription drugs should not be causing such high rates of medical complications and deaths as a result of people not being adequately informed. Home medication errors made by patients are linked to hundreds of thousands of deaths a year and cost this country nearly 180 billion in extra medical treatments.
In an attempt to avoid such misuse, accurate and detailed information is typically provided on labels affixed by a pharmacist to containers of prescription medication specifying the exact manner in which the prescription medication should be used.
Each pharmacy typically has its own label design that may be tailored to its specific needs as well as designed to be in compliance with any regulatory or statutory requirements. The label provides the prescription user with instructions and other necessary information to avoid misunderstandings that could lead to misuse of the medication. The information typically contained on the label includes the name, address and telephone number of the pharmacy, a prescription number, a date on which the prescription is prepared, an expiration date of the prescribed medication, the patient's name and address, the dosage and time schedule (e.g., 2 tablets every four hours), the prescribing doctor's name, the number of permissible refills, if any, the name of the medication, the number of capsules or tablets in the bottle, the weight of each capsule or tablet and indications as to whether the medication should be taken with meals, before meals, after meals, with liquids, not in combination with certain products, refrigerated, and the like.
There is no specific order in which the information provided on the label must be displayed. As such, each pharmacy's label is different. This causes inconveniences when one person has multiple prescriptions, each filled at a different pharmacy. Although the patient might be familiar with a label from one pharmacy and know where to look on that label to find information about taking the medication, he or she would have to search for the same information on a label from a different pharmacy.
In addition, when generating forms for prescription labels, pharmacies often do not prioritize the information, i.e., create an order in which the information is to be printed, for example, based on relevancy.
Thus, in a significant number of current prescription labels, there is no hierarchy of importance of the information contained thereon. Rather, it is often the case that the information about the pharmacy, including its logo, if any, is the most prominently displayed information.
Another inconvenience for patients taking medication relates to warning stickers which are applied to the containers at the pharmacy. Such warning stickers generally have a standard form and some warning stickers are bright orange or red with black printing. When placed on the containers, it is difficult to read the warnings since the black type does not stand out against the bright colors of the warning stickers, i.e., there is not sufficient contrast. Moreover, the red and orange warning stickers do not stand out against amber containers which are used in some pharmacies.
Another possible inconvenience arises when the stickers are affixed to the container and inadvertently cover up a significant amount of text on the label. This creates a problem for patients to read the information printed on the labels. In addition, the warning sticker also becomes difficult to read.
From the warning stickers to the placement of text on the labels to the size of the type used on the labels, there is no consistency in the labeling of prescriptions. As such, important information regarding the use of a medication is often overlooked since there is no indication that such information is important or even critical to the use of the medication. It would therefore be advantageous to provide a prescription labeling system in which information is placed in the order of importance so that important information is placed before information of lesser importance and is therefore not susceptible to being overlooked.
Another problem with prior medication systems is that the medication containers are usually cylindrical in shape such that the label is wrapped around the entire bottle. In this manner, the information printed on the label is difficult to read since, in order to read all of the information, the bottle must be held and rotated. It would be advantageous if all of the information about the prescription on a bottle were to be visible to a patient without having to rotate the bottle.
After dispensing the proper medication, most pharmacies place the filled container in a paper bag with printed information about the prescription as well as additional information about the prescription such as the price. The bag itself is typically branded with the pharmacy's identity and possible advertisements. The bag also may include information about the fastest way to refill the medication. The customer receipt and prescription information page are attached to the bag. The prescription information page is often a sheet of paper about 8.5 inches by 12 inches, folded, with text on both sides. The text is small and laid out with around 26 words per line. The prescription information page is thus often disregarded in view of the sheer amount of text thereon and the relatively small type. Such presents a problem as the information on the prescription information page is extremely important as it describes various properties of the particular drug such as what it is, how to use it, side effects, precautions, drug interactions, overdose, missed dose and storage. Sometimes, this is the only form of communication the patient has with the pharmacist.
One aspect of the present invention relates to a method for packaging a medication including receiving a prescription for a patient including a name of the medication for the patient and a name of the patient, wherein the patient is one of a plurality of family members. The method further comprises receiving a family member listing from the patient identifying one or more other ones of the plurality of family members, assigning a color to the patient that differs from any of one or more colors assigned to any of the other ones of the plurality of family members identified in the family member listing, and packaging the medication for delivery to the patient including securing a color-coded member to the container for the medication. The color-coded member is the color assigned to the patient. Other embodiments and systems are also disclosed.
The invention, together with further objects and advantages thereof, may best be understood by reference to the following description taken in conjunction with the accompanying drawings wherein like reference numerals identify like elements.
Referring first to
The arrangement and content of the label is designed to prevent the unfortunately all too common problem of people getting sick and sometimes dying due to mistakes such as misreading a dosage or not seeing a warning label when taking medication. Thus, the label is designed to make the medication user's experience less confusing. This is done by generally combing the ideas of information architecture with cognitive functions of older adults. The label is the result of a significant amount of research, which determined the layout of instructional information.
Based on the research, an intuitive label is provided in which information to be presented thereon is divided into two categories, primary and secondary. The primary information reflects relatively important information, i.e., exactly what the patient wants and needs to know first to avoid misuse of the medication such as the name of the drug, its purpose, dosage and how to take it. The secondary information reflects information of lesser importance, such as the expiration date, quantity, name of the doctor prescribing the medication, how to reach the doctor, etc. The secondary information also includes the drug store, the refill number and the dispensing date. The hierarchy of the information, e.g., the order, position, type size, contrast, leading, alignment and choice of typefaces, is another important factor to a functional and clear label. In combination, the order of presentation of information and the manner in which the information is presented, coupled with the consumer's point of view, is crucial to the success of labeling system in accordance with the invention in the prevention of misuse of medication.
To achieve this purpose, the labels 10 are partitioned into a plurality of discrete information areas and a label dispensing machine can be used which prints the partitions lines when printing the information on the label. In the alternative, the labels can be pre-printed with the partition lines between the information areas. In general, the label 10 is formed on a substrate having an adhesive backing layer so that when the backing layer is removed, the label 10 can be affixed to a container via the adhesive layer.
A first information area 12 is arranged at the top of the label 10, extending almost entirely across the top of the label 10. Information area 12 is printed with the patient's full name and the patient's home address below the patient's name.
Information area 14 is arranged below information area 12 and is a shaded region in which the identification or name of the medication is printed. The identification of the medication may be the trademarked name of the medication, if this version is prescribed, or the equivalent generic name if a generic is available and prescribed or dispensed.
Information area 14 also includes an icon or pictogram 14a of the medication proximate the right edge of the information area 14. The presentation of the pictogram 14a serves to distinguish generally, for example, between capsules and tablets. By providing a pictogram 14a of the medication on the label 10, errors arising from taking the wrong medication can be prevented when two or more prescribed medications have different forms. For example, if a capsule is prescribed for one illness and a tablet for another, then the patient could view the pictogram 14a of the medication on the label 10 and know which medication is the right one to take. The patient would not have to consider even the name of the medication. Of course, this is not possible when the same type of medication is prescribed, such as two tablet-form medications.
In addition, the use of pictograms will enable patients to detect mistakes in the dispensing of the medication, e.g., if the form of the medication does not correspond to the pictogram. Possible pictograms 14a are discussed below with reference to
Below information area 14 is information area 16, which contains a brief description of the purpose of the medication. A variety of purposes are designated for application by the label printing machine and may include “sleep-aid”, “blood pressure control”, “anti-biotic”, “lowers cholesterol”, “antihistamine”, “cough-cold”, “migraine”, “anti-anxiety”, “anti-psoriasis” and “anti-arrhythmic” At the right edge of information area 16 is the dosage 16a of the medication, i.e., the strength or weight of the medication (10 mg, 20 mg, 100 mg, etc.).
A large information area 18 is arranged below information area 16 and includes the word “take” followed by instructions on the manner in which the medication should be taken. Precise and detailed instructions in plain language may be provided in view of the large size of information area 18. For example, possible instructions may be “1 to 2 tablets at bedtime as needed”, “2 tablets before meals”, “1 tablet every 12 hours”, “swallow 2 tablets every six hours” and the like. The information area 18 can also include a notation of “HIGH ALERT” (as shown in the middle label 10 of the container shown in
The information in information areas 12, 14, 16, 18 may be considered the primary information in that it is the basic information needed to properly administer or take the medication. The name of the patient for which the medication is prescribed is necessary to avoid the situation where one person takes another medication. The name of the medication is necessary to avoid the situation where the wrong medication is taken The purpose of the medication is necessary to clarify the condition and reason why the medication is being taken so that if the condition is no longer present, the medication would not be required. This happens when a medication is taken as a pain reliever so that once the pain is no longer present, the medication can be stopped. The instructions about how to take the medication are necessary to avoid the situation where the medication is taken improperly and thus may not provide its intended and expected benefits.
Additional information is also printed on the label 10 and is considered the secondary information in that it is less important for correct usage of the medication than the primary information. To this end, information area 20 is arranged below information area 18 and includes information about the expiration date of the medication, the date beyond which the medication may not be effective. Information area 22 is below information area 20 and includes information about the number of possible refills of the medication and the quantity of tablets or capsules in the prescription. The label 10 includes the word “expires:” following by space for the expiration date, the word “refill:” following by a space for number indicative of the number of refills available, and the word “qty:” or “quantity” following by a space for the quantity of tablets or capsules in the prescription.
Information area 24 is below information area 22 and includes information about the doctor prescribing the medication, including for example, his or her phone number and optionally the address, the date the prescription is written and the doctor's DEA number.
Information areas 12-24 are substantially rectangular and have a common length. The width of the information areas 12-24 varies as shown in
Another information area 26 is arranged at the right of information areas 12-24 and the print therein is vertically oriented. Information area 26 includes the logo of the store or pharmacy dispensing the prescription and information about the store or pharmacy including for example, the prescription number, the phone number and optionally the address, and the date the prescription is dispensed.
To complete the label 10, other printed information can also be provided if desired, needed and/or required by law. For example, as shown in
In addition to the arrangement and content of the information areas 12-26, the font, type and capitalization used to print the information is selected to optimize the conveyance of information about the prescription and its usage. Specifically, the printed information has different types with more important information printed in a larger type than information of lesser importance. As an example, in the label illustrated in
With respect to the font, it has been found that the Myriad Roman font is an extremely advantageous font since it provides clear letters when used either plain, in an italics mode or in a bold or semi-bold mode. The particular mode of the Myriad Roman font used for the information printed in each information area is preferably selected to optimize the conveyance of information on the label. (In the label illustrated in
In the embodiment illustrated in
In addition, the numbers relating to the instructions for taking the medication, in information area 18, may also be printed in bold type. This will serve to highlight for example, the number of tablets and/or the hours between taking the medication. An instruction can therefore be, for example, “1 or 2 capsules every 4 hours as needed”. This clearly conveys to the patient the proper administration of the medication.
As also shown in
As noted above, the indication in information area 28 is printed in black ink on a color background. It is possible to obtain numerous different colors using any commercially available color printer which can be adapted to print prescription labels. Possible colors used in the invention are green, orange, blue, gray, pink, and yellow and these colors, as well as possibly other colors, can easily be produced by most any color printer.
The color of the information area 28 can be used to convey specific information designed to prevent misuse of the medication. For example, each member of a family can be assigned a different color and whenever that member has a prescription filled, the information area 28 will be printed in that color. In this manner, each member will know only to take medication having his or her color. This will enable each patient to take the correct medication in a situation where two members of the same family are taking the same medication but different doses, e.g., one is taking Ambien 10 mg and the other is taking Ambien 50 mg. By color-coding at least a portion of the label, and associating each individual color with a particular family member, each family member will know only to take medication having his or her assigned color thereon.
Assignment of different colors to different family members may be done when the family first fills a prescription at a pharmacy incorporating the labeling system in accordance with the invention. The family member would complete a form listing the family members and each would select or be assigned a color for the label. The system would prevent the selection or assignment of the same color to more than one family member. If a patient-consumer lives alone, he or she can always choose a default color. Instead of assigning different colors to different family members, it is also possible to use color-coding for morning pills and nighttime pills. This might be used by a person living alone. As such, he or she could code labels pertaining to morning pills one color and their evening pills another color. Alternatively, color-coding can be used universally to differentiate between different families of medications.
The use of a particular color on the label is a quick and easy way for a patient to identify a particular medication since color is mentally processed in a short amount of time. Use of color therefore helps avoid confusion when multiple medications are present. Instead of limiting the color-coded portion to information area 28, other portions of the labels can be colored, for example, the borders or possibly information area 14.
In some instances, it might be desirable to use a specific color, such as red, on a portion of the label to identify high-risk medications.
As noted above, by displaying a pictogram of the medication on the label, when multiple medications are prescribed having different forms, the pictogram provides a quick and easy way to determine the medication (assuming it is known that one medication is in one form and the other medication is in another form). In addition, displaying a pictogram of the medication on the label allows the patient to detect if the medicine in the container to which the label 10 is affixed does not match the pictogram 14a. If so, the patient will hopefully avoid taking the medication and clarify the situation as to which medication should be taken.
Referring now to
The label 10, when generated, is provided with a time-released expiration mark 62, such as stripes of red color against a white background, which appear on the label 10 when the medication has expired. While initially the label 10 has a generally white background, stripes of color will appear upon expiration of the medication notifying the user that the medication has expired. If the label has a big red “X” going through it, it should be clear to the patient that the medicine is no longer effective and could be dangerous.
The application of a time-release expiration mark to labels has been developed by Temtec Inc. of Suffern, N.Y. which makes a product called TempBadge. The following U.S. patents owned by Temtec are incorporated herein by reference: U.S. Pat. Nos. 4,605,246, 5,446,705, 5,602,804, 5,633,835, 5,640,742, 5,699,326, 5,715,215, 5,719,828, 5,755,175, 5,785,354, 5,822,280, 5,862,101, 5,873,606, 5,930,206, 5,947,369, 5,957,458, 6,086,971, 6,197,396 and 6,295,252.
Referring now to
The container 32 in accordance with the invention thus does not have the conventional cylindrical form. Several advantages are provided by the container 32 in accordance with invention. The user should feel comfortable using the container 32 since it is similar to the existing cylindrical containers, and not entirely different as would be the case if a container having a rectangular cross-section were to be used.
It has also been found that it is easier to read information on a semi-circle as opposed to having information printed all around a cylindrical container which would require the container to be turned in a complete circle to obtain all of the information printed thereon. Turning the container creates fragmented instructions.
In addition, the rear of the container 32 is planar and includes a retaining device which enables an information card and/or magnifying lens to be retained in a fixed position relative to the container. The information card would thus be easy to read without requiring any turning of the container 32.
Moreover, the semi-circular shape of the container 32 takes up less space in medicine cabinets and on kitchen counters where medication is usually stored.
The rear wall 36 of the container 32 includes at least one retaining device for enabling an information card 48 or magnifying lens to be retained in a fixed position relative to the container. A shoulder 44 is formed along each lateral edge of the rear wall 36 extending from the bottom of the rear wall 36 to the top of the rear wall 36 and each shoulder 44 includes a groove or ridge 46. An information card 48 (discussed below) or any other relevant material can slide in and out of a slot 50 formed by the grooves 46. Instead of opposed grooves 46 for holding the information card 48, other constructions, such as a pocket, could also be provided. It is also possible to attach the card directly to the rear wall of the container using a magnet or Velcro arrangement. The slot 50 may be dimensioned to accommodate any size of paper.
The slot 50 formed by the grooves 46 can be used by pharmacists to display special notes on the information card 48 for the patient. The note would be printed on the information card upon printing of the label 10. For example, the time the patient should take their medication can be printed on the card 48. The card 48 can also include warnings regarding the medication.
The slot 50 can also be used to hold a magnifying lens 52 which magnifies the medication in the container 32 to make it more clearly visible to the patient (see
In the preferred embodiment of the invention, the information card 48 is not affixed to the container 32 but rather is removably received in the slot 50. This is possible because the information card 48 would typically contain information supplemental to that on the label 10 so that as long as the label 10 is still affixed to the container 32, the medication can be properly taken. However, when the information card is not affixed to the container, warning stickers appearing on the back of the information card are also affixed to the planar surface of the container so that, if the card is removed, the warning stickers remain visible to the patient.
In another embodiment of the invention, the information card 48 is affixed to the container. In this embodiment, the card 48 is affixed at one of its edges and the card is folded so that it rests flush with the planar edge of the container. The patient unfolds the card 48 in order to read its contents.
The containers 32 may be constructed in various sizes. Medication containers are measured in drams and the number of drams reflects the content size of the bottle. At least three different size containers 32 are envisioned, namely, a large size (90 dram, about 4 inches by 2.75 inches), a medium size (30 dram, about 3.75 inches by 2 inches) and a small size (10 dram, about 3 inches by 1.75 inches). The size of the container 32 used by the pharmacist is selected according to the amount of medication prescribed.
In view of the different sizes of containers 32, the label 10 is also provided with different sizes, one to fit each of the different containers.
To produce the containers 32, an initial prototype mold of the container is made. The initial mold has a single cavity into which plastic is injected. A cavity is the space that forms the product by having plastic injected into it. A container designer works with the prototype until it meets with approval. Once a perfected prototype is complete, a multi-cavity mold can be made. The price of the mold varies according to the size of the container and how many cavities there are. Once a mold is approved, production of the containers can proceed. The containers 30 may be made of inexpensive recyclable plastic purchased from any number of suppliers. A common type is polypropylene.
Another novel feature of the invention is the particular construction and content of the information card 48 (see
In contrast to the prior art practice of providing information regarding the prescribed medication printed on sheets of paper with long lines of small type, the information card 48 in accordance with the invention is an easy-to-read, fold-out card that fits into the slot 50 formed by the grooves 46 on the rear wall 36 of the container 32. In view of the different sizes of containers 32, the card 48 will also be fabricated in three different sizes, one to fit each container 32. The card 48 thus has a width of approximately twice the width of the slot 50 so that when folded in the middle, it will be securely retained in the slot 50. The card can also be folded more than two times in which case, its width will be equal to the width of the slot 50 times the number of folded sections.
The information card 48 serves several purposes. The card provides the patient with warnings and side effects about the medication. When a patient opens the card, he or she can read information and facts about the particular drug. The warnings are placed on top of one another facing outward and thus are the first thing the patient sees when he or she turns the container 32 around. Even if the patient does not remove the information card 48 from the slot 50, he or she will be able to see the warnings. These warnings are designed to replace the current warning stickers.
The information card 48 also provides a space for pharmacists to enter additional notes that will help the patient comply with, e.g., dosage instructions. As shown in
An additional card can be stapled to the bag in which the prescription is delivered and/or sold. This copy may be kept in the patient's wallet in case of an emergency. Since the card is easily accessible, it can be used as a reference whenever necessary.
The information card 48 may be made formed of a waterproof material or sealed to be waterproof so it can be stored in a bathroom without risk of getting wet. Ideally, a patient collects an additional copy of each card and, by reviewing the card, is readily able to ascertain what medications he or she is taking.
The information card 48 can be used with containers having different shapes than container 32. For example, information card 48 can be used in connection with any container having a flat side, such as a rectangular or square container. The information card 48 can also be used for cylindrical containers in which case, shoulders 44 can be formed at two peripheral locations around the container and the information card would be bent around a portion of the circumference of the container. Thus, the information card 48 can be used independent of the label 10 and container 32 described above.
Accordingly, a comprehensive labeling and packaging system for prescription medication is provided in accordance with the invention which seeks to benefit consumers by delivering instructions, warnings and knowledge about medications in a clear and simple manner in order to avoid the incorrect use of medication. By creating a clear, well thought-out system for labeling and packaging medications, an improved dispensing system will be created which will provide benefits to all parties involved. The medical industry will experience a decrease in medical errors, health insurance companies will profit as a result of lower hospital bills, drug companies will face fewer lawsuits, pharmacists and doctors will be able to identify different drugs and dosages and consumer's experience with the health care industry will be more satisfying
As to consumers, the system in accordance with the invention will likely provide the greatest benefit to prescription users over the age of 65. This group is at the highest risk of medication errors. There are currently more than 35 million Americans over the age of 65, and approximately 6.3 million may not be able to correctly read the directions that appear on their medicine labels. This problem is only going to worsen as the baby boomer generation grows older.
The system in accordance with the invention is designed to be easily readable for people 65 and older. In view of the presence of pictograms and the use of bold, clear typeface, among other features, illiterate and non-English-speaking citizens can also benefit from the invention. There are currently 40 million Americans who are functionally illiterate (reading at or below a fifth-grade level). Yet, like everyone, they need to understand how many times a day they should take their medication and what the side effects are.
Consumers will also benefit by the presence of distinguishing marks on the label that may alert the pharmacist of the need to provide particular, important information. For example, most pharmacists use automatic label printing machines which generate labels. In accordance with the invention, labels for some medications would be generated with marking indicating a “HIGH ALERT” (in information area 18) or a particular color in a specific region (the color red in information area 28). Upon seeing one of these markings, the pharmacist is informed of the need to explain information about the product to the patient to avoid possible misuse.
In the practice of the invention, a label 10 is formed on a single sheet with the information regarding the medication. Such a sheet is shown in
While particular embodiments of the invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications may be made without departing from the invention in its broader aspects. For example, the invention is not limited to prescription medications for humans but can also be applied to over-the-counter medications and medications for animals. Therefore, the aim in the appended claims is to cover all such changes and modifications as fall within the true spirit and scope of the invention.
This application is a continuation of and claims priority under 35 U.S.C. § 120 to U.S. patent application Ser. No. 14/203,146, filed Mar. 10, 2014, which is a continuation of U.S. patent application Ser. No. 13/245,625, filed Sep. 26, 2011, which is a continuation of and claims priority to U.S. patent application Ser. No. 10/437,474, filed May 14, 2003, now U.S. Pat. No. 8,025,314, issued Sep. 27, 2011, all of which are incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
D11149 | Hood | Apr 1879 | S |
D18997 | Underhill | Apr 1889 | S |
406017 | Woodward et al. | Jun 1889 | A |
493851 | Adsit | Mar 1893 | A |
605213 | Weller | Jun 1898 | A |
624701 | Stevenson | May 1899 | A |
716793 | Vogeler | Dec 1902 | A |
D45565 | Lloyd | Apr 1914 | S |
1181098 | Lambert | Apr 1916 | A |
1223933 | Carr | Apr 1917 | A |
1289218 | Maiden | Dec 1918 | A |
1411510 | Peterson | Apr 1922 | A |
1554191 | Alexander | Sep 1925 | A |
1653608 | Allen | Dec 1927 | A |
1686354 | Wallace | Oct 1928 | A |
1769147 | Lennon | Jul 1930 | A |
1815268 | Newbery | Jul 1931 | A |
1850369 | Andrews | Mar 1932 | A |
1991871 | Sindler | Feb 1935 | A |
1993978 | Plochman | Mar 1935 | A |
2007685 | Lyle | Jul 1935 | A |
2110768 | Kellogg | Mar 1938 | A |
D128282 | Gelinas et al. | Jul 1941 | S |
2270277 | Dowd | Jan 1942 | A |
D132185 | McIntosh | Apr 1942 | S |
2328806 | Hoofer | Sep 1943 | A |
2528259 | Annunziata | Oct 1950 | A |
2659614 | Cook et al. | Nov 1953 | A |
2717463 | Sindler | Sep 1955 | A |
2793842 | Bacon | May 1957 | A |
2794545 | Olson | Jun 1957 | A |
2844893 | Keller | Jul 1958 | A |
2847971 | Painter | Aug 1958 | A |
2908985 | Hartman | Oct 1959 | A |
2920777 | Cole | Jan 1960 | A |
2961108 | Johnson | Nov 1960 | A |
2995265 | Soderberg | Aug 1961 | A |
3256978 | Srigley et al. | Jun 1966 | A |
3298671 | Popma et al. | Jan 1967 | A |
3331521 | Paige | Jul 1967 | A |
3386837 | Amot | Jun 1968 | A |
3423861 | Forsyth | Jan 1969 | A |
3433378 | Ross | Mar 1969 | A |
3437194 | Ames et al. | Apr 1969 | A |
3625547 | Burke | Dec 1971 | A |
3628266 | Wise | Dec 1971 | A |
3757994 | Skoetsch | Sep 1973 | A |
3772809 | Schneller | Nov 1973 | A |
D230137 | Bettonica | Jan 1974 | S |
3787993 | Lyon | Jan 1974 | A |
3822780 | Ulmer et al. | Jul 1974 | A |
3826222 | Romick | Jul 1974 | A |
3850326 | Ryles | Nov 1974 | A |
3923180 | Fields | Dec 1975 | A |
3958690 | Gee, Sr. | May 1976 | A |
3996879 | Walton | Dec 1976 | A |
4022352 | Pehr | May 1977 | A |
4044889 | Orentreich et al. | Aug 1977 | A |
4061783 | Hoffman et al. | Dec 1977 | A |
4064645 | Wood | Dec 1977 | A |
RE29793 | Pehr | Oct 1978 | E |
4143786 | Goldberg et al. | Mar 1979 | A |
4150760 | d'Orgelys | Apr 1979 | A |
D255054 | Kingsford | May 1980 | S |
4246709 | Selleslags | Jan 1981 | A |
4263734 | Bradshaw | Apr 1981 | A |
4284200 | Bush et al. | Aug 1981 | A |
4285489 | Blanchard | Aug 1981 | A |
4334638 | Stock | Jun 1982 | A |
D270998 | Stark | Oct 1983 | S |
4428384 | Raitto | Jan 1984 | A |
D274309 | Aldrich, III | Jun 1984 | S |
4483622 | Muhi et al. | Nov 1984 | A |
4535903 | Franchi | Aug 1985 | A |
D280601 | Biesecker | Sep 1985 | S |
4550602 | Burke, Sr. et al. | Nov 1985 | A |
D282909 | Biesecker | Mar 1986 | S |
D285535 | Buchholz et al. | Sep 1986 | S |
4732411 | Siegel | Mar 1988 | A |
D295024 | Trick | Apr 1988 | S |
D295954 | Kirchhoff | May 1988 | S |
4753358 | Virca et al. | Jun 1988 | A |
4799712 | Biava et al. | Jan 1989 | A |
4802438 | DeJonge | Feb 1989 | A |
D300119 | Pacquin | Mar 1989 | S |
4813570 | Pontoppidan | Mar 1989 | A |
4819351 | Boitani | Apr 1989 | A |
4860899 | McKee | Aug 1989 | A |
4863026 | Perkowski | Sep 1989 | A |
4868027 | Hunkeler et al. | Sep 1989 | A |
4881648 | Hagerty | Nov 1989 | A |
4883180 | Humphrey et al. | Nov 1989 | A |
4889237 | Brandon | Dec 1989 | A |
D305505 | Kunesh | Jan 1990 | S |
4890742 | Allison | Jan 1990 | A |
4913083 | Valvo et al. | Apr 1990 | A |
4918604 | Baum | Apr 1990 | A |
4919285 | Roof et al. | Apr 1990 | A |
4941573 | Fuerstman | Jul 1990 | A |
4972657 | McKee | Nov 1990 | A |
D312776 | Tacconelli | Dec 1990 | S |
4991877 | Lieberman | Feb 1991 | A |
5011032 | Rollman | Apr 1991 | A |
5020682 | Dutt | Jun 1991 | A |
D319181 | Balavich | Aug 1991 | S |
5048870 | Mangini et al. | Sep 1991 | A |
D323780 | Addante | Feb 1992 | S |
D324994 | Jentgen | Mar 1992 | S |
5102169 | Mayfield | Apr 1992 | A |
D328246 | Nottingham et al. | Jul 1992 | S |
5145080 | Imbery, Jr. | Sep 1992 | A |
5165546 | Jaeger et al. | Nov 1992 | A |
5172936 | Sullivan et al. | Dec 1992 | A |
5178311 | McBride | Jan 1993 | A |
D333618 | Patel et al. | Mar 1993 | S |
5193032 | Hirth | Mar 1993 | A |
5204775 | McDevitt | Apr 1993 | A |
5215334 | Presson et al. | Jun 1993 | A |
5261702 | Mayfield | Nov 1993 | A |
D342452 | Monaghan | Dec 1993 | S |
D343360 | Poo | Jan 1994 | S |
5284363 | Gartner et al. | Feb 1994 | A |
5301802 | Nemeroff | Apr 1994 | A |
5301840 | Sun | Apr 1994 | A |
5309279 | Halstead | May 1994 | A |
5342093 | Weernink | Aug 1994 | A |
D350691 | Simion | Sep 1994 | S |
5343647 | Bulka | Sep 1994 | A |
5346069 | Intini | Sep 1994 | A |
D351796 | Deddens | Oct 1994 | S |
5351991 | McDonald | Oct 1994 | A |
D355125 | Patel et al. | Feb 1995 | S |
D355126 | Paulovich et al. | Feb 1995 | S |
D355363 | Iorii et al. | Feb 1995 | S |
5386795 | Bartholomew | Feb 1995 | A |
5403636 | Crum | Apr 1995 | A |
D360134 | Snyder | Jul 1995 | S |
5448844 | Miller, Jr. et al. | Sep 1995 | A |
5476420 | Manning | Dec 1995 | A |
5495944 | Lermer | Mar 1996 | A |
D370636 | Crawford | Jun 1996 | S |
5588239 | Anderson | Dec 1996 | A |
5601314 | Burns et al. | Feb 1997 | A |
5632420 | Lohrman et al. | May 1997 | A |
5642906 | Foote et al. | Jul 1997 | A |
5660138 | Hirsch | Aug 1997 | A |
5662239 | Heuvelman | Sep 1997 | A |
D389064 | Sethi et al. | Jan 1998 | S |
5704144 | Groth | Jan 1998 | A |
5704648 | Brown et al. | Jan 1998 | A |
5713681 | Venne et al. | Feb 1998 | A |
5718347 | Walker et al. | Feb 1998 | A |
5719828 | Haas et al. | Feb 1998 | A |
5729922 | Peterson et al. | Mar 1998 | A |
5730292 | Jones | Mar 1998 | A |
5758440 | Yudin | Jun 1998 | A |
5760975 | DiGiovanni | Jun 1998 | A |
D395828 | Lecoule | Jul 1998 | S |
5779072 | Krebs | Jul 1998 | A |
5788974 | D'Amico et al. | Aug 1998 | A |
5799815 | Lang | Sep 1998 | A |
5800144 | Glenn et al. | Sep 1998 | A |
5829789 | Treleaven et al. | Nov 1998 | A |
5887736 | Mar | Mar 1999 | A |
5918758 | Galton-Fenzi | Jul 1999 | A |
D413067 | Haley | Aug 1999 | S |
5980352 | Rigberg | Nov 1999 | A |
6003902 | Petkovsek | Dec 1999 | A |
D419077 | Sultan | Jan 2000 | S |
6023865 | Preuss | Feb 2000 | A |
D423361 | Negre | Apr 2000 | S |
D425427 | Heeter et al. | May 2000 | S |
6068300 | Vijuk et al. | May 2000 | A |
D427073 | Gaffney et al. | Jun 2000 | S |
6081392 | Pensmith | Jun 2000 | A |
6086702 | Rea | Jul 2000 | A |
D430802 | Adachi et al. | Sep 2000 | S |
6127013 | Todd | Oct 2000 | A |
6158779 | Petrick | Dec 2000 | A |
6171559 | Sanders et al. | Jan 2001 | B1 |
6196593 | Petrick et al. | Mar 2001 | B1 |
6209921 | Hogan et al. | Apr 2001 | B1 |
6220439 | Virvo | Apr 2001 | B1 |
6226564 | Stuart | May 2001 | B1 |
6241844 | Petkovsek | Jun 2001 | B1 |
D445338 | Helleu | Jul 2001 | S |
6253958 | Coletti | Jul 2001 | B1 |
6270121 | Dolan et al. | Aug 2001 | B1 |
6276725 | Laurash et al. | Aug 2001 | B1 |
6278545 | Napier | Aug 2001 | B1 |
D447694 | Leggett | Sep 2001 | S |
D451809 | Jones | Dec 2001 | S |
6360462 | Mengel | Mar 2002 | B1 |
D456271 | Maloney | Apr 2002 | S |
6366401 | Gonda et al. | Apr 2002 | B1 |
6367639 | Mar | Apr 2002 | B1 |
6367640 | Julian | Apr 2002 | B1 |
6379007 | Farb | Apr 2002 | B1 |
D457063 | Bakic | May 2002 | S |
6386367 | Bayliss, IV | May 2002 | B1 |
D459212 | Gobe | Jun 2002 | S |
6402872 | Key | Jun 2002 | B1 |
6471391 | Opitz | Oct 2002 | B1 |
6491164 | Virvo | Dec 2002 | B1 |
6532117 | Taylor | Mar 2003 | B2 |
6549345 | Cardarelli | Apr 2003 | B1 |
D474690 | Bakic | May 2003 | S |
6568530 | Takahashi et al. | May 2003 | B2 |
6594928 | Clawson et al. | Jul 2003 | B1 |
D480002 | Canepa | Sep 2003 | S |
D480005 | Conway | Sep 2003 | S |
6621629 | Blumenthal et al. | Sep 2003 | B2 |
D480960 | Gray et al. | Oct 2003 | S |
D481165 | Angeletta | Oct 2003 | S |
6669804 | Pendry et al. | Dec 2003 | B2 |
D485764 | Bakic | Jan 2004 | S |
6681945 | Harrold | Jan 2004 | B1 |
6712398 | Fox et al. | Mar 2004 | B1 |
6722495 | Fresnel | Apr 2004 | B2 |
6745505 | Moran | Jun 2004 | B2 |
6752272 | Jones et al. | Jun 2004 | B2 |
6789497 | Aiken | Sep 2004 | B1 |
6793075 | Jeter | Sep 2004 | B1 |
D497311 | Walsh et al. | Oct 2004 | S |
6860390 | Bowman | Mar 2005 | B2 |
6860513 | Kaufman | Mar 2005 | B2 |
6868627 | Elias | Mar 2005 | B2 |
6923376 | Gosden et al. | Aug 2005 | B2 |
6951353 | Kozlowski et al. | Oct 2005 | B2 |
6964345 | Wetherell, Jr. et al. | Nov 2005 | B2 |
D520365 | Andoh | May 2006 | S |
D522867 | Bakic | Jun 2006 | S |
7061831 | De La Huerga | Jun 2006 | B2 |
D526569 | Wurster et al. | Aug 2006 | S |
D537349 | Ball et al. | Feb 2007 | S |
D539651 | Snyder | Apr 2007 | S |
D540179 | Adler et al. | Apr 2007 | S |
D540690 | Adler et al. | Apr 2007 | S |
D541159 | Robinson | Apr 2007 | S |
D542661 | Adler et al. | May 2007 | S |
7222736 | Seijas | May 2007 | B1 |
7225052 | Foote et al. | May 2007 | B2 |
7225937 | Schroeder | Jun 2007 | B2 |
D550571 | Diaz | Sep 2007 | S |
D554999 | Nukuto et al. | Nov 2007 | S |
D555498 | Bansal | Nov 2007 | S |
7311205 | Adler et al. | Dec 2007 | B2 |
D559117 | Nukuto et al. | Jan 2008 | S |
7320483 | Eippert | Jan 2008 | B2 |
D566330 | Angeletta | Apr 2008 | S |
D572593 | Adler et al. | Jul 2008 | S |
D574717 | Adler et al. | Aug 2008 | S |
7413082 | Adler et al. | Aug 2008 | B2 |
D581275 | Adler et al. | Nov 2008 | S |
D583242 | Adler et al. | Dec 2008 | S |
D594336 | Adler | Jun 2009 | S |
D597841 | Adler et al. | Aug 2009 | S |
7628427 | Adler et al. | Dec 2009 | B2 |
7661533 | Adler et al. | Feb 2010 | B2 |
7942451 | Adler | May 2011 | B2 |
7980391 | Adler et al. | Jul 2011 | B2 |
8025314 | Adler | Sep 2011 | B2 |
20010017817 | De La Huerga | Aug 2001 | A1 |
20010054817 | Kelley et al. | Dec 2001 | A1 |
20020020088 | Kreutner | Feb 2002 | A1 |
20020041091 | Eippert | Apr 2002 | A1 |
20020063739 | Gosden et al. | May 2002 | A1 |
20020085290 | Taylor | Jul 2002 | A1 |
20020088732 | Takahashi et al. | Jul 2002 | A1 |
20020129758 | Hanley et al. | Sep 2002 | A1 |
20020162261 | West et al. | Nov 2002 | A1 |
20020171238 | Kozlowski et al. | Nov 2002 | A1 |
20020173875 | Wallace et al. | Nov 2002 | A1 |
20030025320 | Shoemaker | Feb 2003 | A1 |
20030028392 | Davies | Feb 2003 | A1 |
20030091687 | Copelan | May 2003 | A1 |
20030127351 | Takahashi et al. | Jul 2003 | A1 |
20030147450 | Witonsky et al. | Aug 2003 | A1 |
20030149599 | Goodall et al. | Aug 2003 | A1 |
20030192211 | Elias | Oct 2003 | A1 |
20030193181 | Hung | Oct 2003 | A1 |
20030193185 | Valley et al. | Oct 2003 | A1 |
20030205897 | Kaufman | Nov 2003 | A1 |
20030214129 | Adler | Nov 2003 | A1 |
20040045863 | Rhoades | Mar 2004 | A1 |
20040050750 | Hannan et al. | Mar 2004 | A1 |
20040056479 | Fox et al. | Mar 2004 | A1 |
20040075272 | Kaufman | Apr 2004 | A1 |
20040193454 | Foote et al. | Sep 2004 | A1 |
20040232023 | Bansal et al. | Nov 2004 | A1 |
20040237311 | Brown et al. | Dec 2004 | A1 |
20050205513 | Hidding | Sep 2005 | A1 |
20060016108 | Watts | Jan 2006 | A1 |
20060163103 | Adler et al. | Jul 2006 | A1 |
20060163110 | Adler et al. | Jul 2006 | A1 |
20060163869 | Adler et al. | Jul 2006 | A1 |
20070029788 | Adler | Feb 2007 | A1 |
20070102316 | Van Der Krogt et al. | May 2007 | A1 |
20080017602 | Adler et al. | Jan 2008 | A1 |
20080264532 | Wilson | Oct 2008 | A1 |
20090090688 | Fruchter | Apr 2009 | A1 |
20100314351 | Hoefling | Dec 2010 | A1 |
Number | Date | Country |
---|---|---|
3723671 | Aug 1988 | DE |
0146095 | Jun 1985 | EP |
0316636 | May 1989 | EP |
0609955 | Apr 1998 | EP |
0609954 | Jul 1998 | EP |
0924676 | Jun 1999 | EP |
2296391 | Jul 1976 | FR |
2006713 | May 1979 | GB |
3004545 | Jan 1991 | JP |
10297640 | Nov 1998 | JP |
0028474 | May 2000 | WO |
0063087 | Oct 2000 | WO |
0064676 | Nov 2000 | WO |
0145028 | Jun 2001 | WO |
03098275 | Nov 2003 | WO |
2004036481 | Apr 2004 | WO |
2004048216 | Jun 2004 | WO |
Entry |
---|
International Search Report and Written Opinion for International Application No. PCT/US2005/019401, dated Jan. 17, 2006, 15 pgs. |
Supplemental European Search Report for EP Application No. 03724594.1, dated Nov. 29, 2010, 5 pgs. |
The Medi-Dose Group, “Multi-Dose, Multi-Color, I.V. Bag Rings,” www.medidose.com/catalog/ivpharm/bagrings.html, publicly advertised online at least as early as Apr. 27, 2002, 1 pg. |
Number | Date | Country | |
---|---|---|---|
20180261311 A1 | Sep 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14203146 | Mar 2014 | US |
Child | 15981554 | US | |
Parent | 13245625 | Sep 2011 | US |
Child | 14203146 | US | |
Parent | 10437474 | May 2003 | US |
Child | 13245625 | US |